aTyr Pharma, Inc.

aTyr Pharma, Inc.

aTyr Pharma, Inc.

Overview
Date Founded

2005

Headquarters

3545 John Hopkins Court, Suite 250, San Diego, CA, 92121, USA

Type of Company

Public

Employees (Worldwide)

44

Industries

Pharmaceuticals
Biotechnology

Company Description

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at aTyr Pharma, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer, Director

Chief Financial & Accounting Officer

Secretary, Vice President & General Counsel

Benefit Plan Administrator

Vice President, Enterprise Talent & Organization

Vice President, Corporate Development

Founder

Senior Director, Investor Relations

Senior Director

Associate Director Financial

Paths to aTyr Pharma, Inc.
Potential Connections via
Relationship Science
You
aTyr Pharma, Inc.
Owners & Shareholders
Details Hidden

Altium Capital Management LP is an American private company located in New York, NY, with subsidiaries in the United States. The firm provides investment advice.

Details Hidden

Altium Capital Management LP is an American private company located in New York, NY, with subsidiaries in the United States. The firm provides investment advice.

Recent Transactions
Details Hidden

aTyr Pharma, Inc. issued USD Common Stock

Details Hidden

aTyr Pharma, Inc. raised money in a private placement transaction

Details Hidden

aTyr Pharma, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onaTyr Pharma, Inc. issued USD Common Stock

Underwriter

Advised onaTyr Pharma, Inc. issued USD Common Stock

Underwriter

Advised onaTyr Pharma, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Founder at Fate Therapeutics, Inc.

Legal Advisor

Partner at DLA Piper

Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Clients

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

KYORIN Holdings, Inc. engages in the development, manufacture and sale of pharmaceutical products through its subsidiaries. It operates through the Pharmaceutical Business and Healthcare Business segments. The Pharmaceutical Business segment engages in the production and sales of prescription drugs, generic drugs, and over the counter drugs. The Healthcare Business segment engages in the development and sales of skincare and cosmetics using drug formulation technology. The company was founded on October 31, 1958 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$36.9M
Total Enterprise Value
$-5.58M
Earnings Per Share
$-7.03
Revenue
$422K
Net Profit
$-23.6M
EBITDA
$-21.6M
TEVNet Income
0.24x
Debt TEV
-2.1x
Total Equity
$21M
Total Debt
$11.7M
EBITDAMargin
-5,121.33%
Enterprise Value Sales
-13.22x
Non-Profit Donations & Grants
Investors
Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

Alta Partners Management Corp. specializes in investments in healthcare venture capital companies. The firm looks for Technology enabled solutions and services that improve delivery and quality of care with Strong entrepreneurs

Competitors
Gilead Sciences, Inc. Biotechnology - Foster City, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Mallinckrodt Plc Pharmaceuticals - Staines-upon-thames, United Kingdom

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by aTyr Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of aTyr Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and aTyr Pharma, Inc..